South Korea
· Delayed Price · Currency is KRW Vaxcell-Bio Therapeutics Statistics
Total Valuation
Vaxcell-Bio Therapeutics has a market cap or net worth of KRW 263.27 billion. The enterprise value is 216.43 billion.
| Market Cap | 263.27B |
| Enterprise Value | 216.43B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxcell-Bio Therapeutics has 22.99 million shares outstanding. The number of shares has increased by 23.04% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 22.99M |
| Shares Change (YoY) | +23.04% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 19.61% |
| Owned by Institutions (%) | 4.77% |
| Float | 18.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.36 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -20.75 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -18.01 |
Financial Position
The company has a current ratio of 22.43, with a Debt / Equity ratio of 0.04.
| Current Ratio | 22.43 |
| Quick Ratio | 22.16 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.23 |
| Interest Coverage | -112.59 |
Financial Efficiency
Return on equity (ROE) is -21.52% and return on invested capital (ROIC) is -16.73%.
| Return on Equity (ROE) | -21.52% |
| Return on Assets (ROA) | -16.22% |
| Return on Capital (ROIC) | -16.73% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.62% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -44.62% |
| 50-Day Moving Average | 13,519.60 |
| 200-Day Moving Average | 16,669.60 |
| Relative Strength Index (RSI) | 30.16 |
| Average Volume (20 Days) | 99,529 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Vaxcell-Bio Therapeutics had revenue of KRW 69.60 million and -10.43 billion in losses. Loss per share was -444.28.
| Revenue | 69.60M |
| Gross Profit | 34.27M |
| Operating Income | -13.39B |
| Pretax Income | -10.43B |
| Net Income | -10.43B |
| EBITDA | -12.56B |
| EBIT | -13.39B |
| Loss Per Share | -444.28 |
Balance Sheet
The company has 49.60 billion in cash and 2.76 billion in debt, giving a net cash position of 46.85 billion or 2,037.40 per share.
| Cash & Cash Equivalents | 49.60B |
| Total Debt | 2.76B |
| Net Cash | 46.85B |
| Net Cash Per Share | 2,037.40 |
| Equity (Book Value) | 78.27B |
| Book Value Per Share | 3,408.50 |
| Working Capital | 49.75B |
Cash Flow
In the last 12 months, operating cash flow was -10.55 billion and capital expenditures -1.46 billion, giving a free cash flow of -12.02 billion.
| Operating Cash Flow | -10.55B |
| Capital Expenditures | -1.46B |
| Free Cash Flow | -12.02B |
| FCF Per Share | -522.73 |
Margins
| Gross Margin | 49.24% |
| Operating Margin | -19,244.85% |
| Pretax Margin | -14,989.18% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -17,269.10% |
Dividends & Yields
Vaxcell-Bio Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.04% |
| Shareholder Yield | -23.04% |
| Earnings Yield | -3.88% |
| FCF Yield | -4.57% |
Stock Splits
The last stock split was on November 10, 2023. It was a forward split with a ratio of 1.2.
| Last Split Date | Nov 10, 2023 |
| Split Type | Forward |
| Split Ratio | 1.2 |
Scores
Vaxcell-Bio Therapeutics has an Altman Z-Score of 54.93.
| Altman Z-Score | 54.93 |
| Piotroski F-Score | n/a |